1	Full Title: Immune and pathophysiologic profiling of antenatal COVID-19 in the GIFT cohort: A
2	Singaporean case-control study.
3	Short Title: Immune consequences and pathophysiology of antenatal COVID-19
4	
5	Yue Gu <sup>1,2</sup> ¶, Jia Ming Low <sup>3,4</sup> ¶, Jolene S.Y. Tan <sup>5</sup> ¶, Melissa Shu Feng Ng <sup>6</sup> , Lisa F.P. Ng <sup>7</sup> ,
6	Bhuvaneshwari D/O Shunmuganathan <sup>1,2</sup> , Rashi Gupta <sup>1,2</sup> , Paul A. MacAry <sup>1,2</sup> , Zubair Amin <sup>3,4</sup> , Le Ye
7	Lee <sup>3,4</sup> , Derrick W.Q. Lian <sup>8</sup> , Lynette Pei-Chi Shek <sup>4,9</sup> , Youjia Zhong <sup>4,5,9</sup> *, Liang Wei Wang <sup>6</sup>
8	
9	<sup>1</sup> Antibody Engineering Programme, Life Sciences Institute, National University of Singapore,
10	Singapore
11	<sup>2</sup> Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National
12	University of Singapore, Singapore
13	<sup>3</sup> Department of Neonatology, Khoo Teck Puat-National University Children's Medical Institute,
14	National University Health System, Singapore
15	<sup>4</sup> Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore,
16	Singapore
17	<sup>5</sup> Duke-NUS Medical School, Singapore
18	<sup>6</sup> Singapore Immunology Network, Agency for Science, Technology and Research, Singapore
19	<sup>7</sup> Infectious Diseases Labs, Agency for Science, Technology and Research, Singapore
20	<sup>8</sup> Department of Pathology, National University Hospital, Singapore
21	<sup>9</sup> Khoo Teck Puat-National University Children's Medical Institute, National University Health
22	System, Singapore

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23
- 24 \*Corresponding author:
- 25 Email: <u>youjia\_zhong@nuhs.edu.sg</u> (YZ)
- 26
- 27 <sup>¶</sup>These authors contributed equally to this work.

# 28 Abstract

### 29 Background

COVID-19 has been a major public health threat for the past two years, with disproportionate effects on the elderly, immunocompromised, and pregnant women. While much has been done in delineating immune dysfunctions and pathogenesis in the former two groups, less is known about the disease's progression in expectant women and children born to them. To address this knowledge gap, we profiled the immune responses in maternal and child sera as well as breast milk in terms of antibody and cytokine expression and performed histopathological studies on placentae obtained from mothers convalescent from antenatal COVID-19.

### 37 Methods and findings

38 A total of 17 mother-child dyads (8 cases of antenatal COVID-19 and 9 healthy unrelated controls; 34 39 individuals in total) were recruited to the Gestational Immunity For Transfer (GIFT) study. Maternal 40 and infant sera, and breast milk samples were collected over the first year of life. All samples were analyzed for IgG and IgA against whole SARS-CoV-2 spike protein, the spike receptor-binding domain 41 (RBD), and previously reported immunodominant epitopes, with conventional ELISA approaches. 42 Cytokine levels were quantified in maternal sera using multiplex microbead-based Luminex arrays. The 43 placentae were examined microscopically. We found high levels of virus-specific IgG in convalescent 44 mothers and similarly elevated titers in newborn children. Virus-specific IgG in infant circulation waned 45 within 3-6 months of life. Virus-specific IgA levels were variable among convalescent individuals' sera 46 47 and breast milk. Convalescent mothers also showed a blood cytokine signature indicative of a persistent 48 pro-inflammatory state. Four placentae presented signs of acute inflammation marked by neutrophil infiltration even though >50 days had elapsed between virus clearance and delivery. Administration of 49 50 a single dose of BNT162b2 mRNA vaccine to mothers convalescent from antenatal COVID-19 51 increased virus-specific IgG and IgA titers in breast milk.

### 52 **Conclusions**

53 Antenatal SARS-CoV-2 infection led to high plasma titres of virus-specific antibodies in infants postnatally. However, this was not reflected in milk; milk-borne antibody levels varied widely. 54 Additionally, placentae from COVID-19 positive mothers exhibited signs of acute inflammation with 55 neutrophilic involvement, particularly in the subchorionic region. Virus neutralisation by plasma was 56 57 not uniformly achieved, and the presence of antibodies targeting known immunodominant epitopes did not assure neutralisation. Antibody transfer ratios and the decay of transplacentally transferred virus-58 specific antibodies in neonatal circulation resembled that for other pathogens. Convalescent mothers 59 60 showed signs of chronic inflammation marked by persistently elevated IL17RA levels in their blood. A single dose of the Pfizer BNT162b2 mRNA vaccine provided significant boosts to milk-borne virus-61 62 specific antibodies, highlighting the importance of receiving the vaccine even after natural infection 63 with the added benefit of enhanced passive immunity. The study is registered at clinicaltrials.gov under the identifier NCT04802278. 64

65

# 66 Introduction

67 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus 68 disease 2019 (COVID-19), has infected over 497 million worldwide (WHO website, as of 13th April 2022) and led to a pandemic. In the midst of this unprecedented crisis, studies on vulnerable groups 69 70 such as pregnant women and newborns are limited compared to the general adult population. Although 71 the manifestation of COVID-19 is less severe in the paediatric population compared to adults, infants are particularly susceptible to developing severe illness [1]. Additionally, concerns over mother-to-child 72 transmission of the virus have led to variable recommendations on postnatal care [2]. Human breast 73 milk (BM) is the main source of nutrients and bioactive factors that protects infants against general 74 infections [3]. Maternal antibodies which are present in abundance in BM are able to confer protection 75

76 against specific infections through their antigen specificity. These maternal antibodies comprise of approximately 90% immunoglobulin A (IgA), 8% IgM and 2% IgG [4]. SARS-CoV-2 antibodies from 77 78 convalescent COVID-19 plasma have been extensively studied as a therapeutic option against COVID-19 infection [5,6]. Several studies have also reported the presence of SARS-CoV-2 antibodies in the 79 80 BM of convalescent COVID-19 mothers [7-9]. However, the durability of those antibodies in the BM 81 and the mechanism of protection remains incompletely known. Hence, we sought to evaluate the 82 durability and neutralization capacity of SARS-CoV-2 specific IgG and IgA in the BM of convalescent 83 COVID-19 mothers.

84 Here, we report that natural infection of pregnant women by SARS-CoV-2 induced antibody production and secretion into maternal blood and milk. However, plasma antibody titres were not 85 closely reflected by that in milk. Placentae from COVID-19 positive mothers exhibited signs of acute 86 inflammation with neutrophilic involvement, despite virus clearance in the nasopharynx. Virus 87 88 neutralisation by plasma was not uniformly achieved, despite high levels of antibodies targeting the 89 spike protein and its receptor-binding domain; the presence of antibodies targeting known 90 immunodominant epitopes did not assure neutralisation. Antibody transfer ratios and decay kinetics of 91 virus-specific antibodies in neonatal circulation largely resembled that described for other pathogens. 92 Targeted analysis of blood cytokines revealed significant elevations in IL17RA levels in convalescent 93 mothers' blood at 16 weeks (range 13-48) from the initial COVID-19 infection, indicating chronic 94 inflammation. Importantly, we also found that a single regular dose of the Pfizer BNT162b2 mRNA 95 vaccine given postnatally boosted milk-borne virus-specific IgG and IgA in mothers convalescent 96 from antenatal COVID-19.

# 97 Materials and methods

### 98 Ethics statement

99 This study was approved by the National Healthcare Group Institutional Review Board (Gestational
100 Immunity For Transfer GIFT: DSRB Reference Number: 2020/00483). Written informed consent was

obtained from all subjects (and where applicable, parents), and the study was conducted in accordance
with the Helsinki Declaration. The study protocol was registered at clinicaltrials.gov (NCT04802278).

### 103 Collection of human breast milk

Breast milk from study participants were collected at 1 month and 3 months postpartum. Milk samples 104 105 were aliquoted and frozen at -20 degrees Celsius until use. Recruited mothers who were convalescent 106 from antenatal COVID-19 (n=8 provided blood samples; n=6 provided BM samples) were confirmed to be positive for COVID-19 infection with real-time reverse-transcriptase polymerase-chain-reaction 107 (RT-PCR) assay on nasopharyngeal swabs during pregnancy. Recovery was defined by the resolution 108 of clinical symptoms and two negative SARS-CoV-2 RT-PCR swabs 24 hours apart. Infants born to 109 110 antenatal COVID-19 convalescent mothers at gestational age between 35 to 40 weeks gestation were included. Mother-child control dyads (n=10) were also recruited. These control mothers had no clinical 111 symptoms of COVID-19 infection and were confirmed to have a negative SARS-CoV-2 IgG at the time 112 of recruitment. 113

### 114 Blood processing for plasma

Venous blood samples from the infant were collected at 0-3 days, 1 month, and 3 months of life, and
from the mothers at 1 month postpartum, in BD Vacutainer cell preparation tubes (BD, #362753). The
plasma fraction was harvested after centrifugation at 1500rpm, 5 minutes at 4°C and stored at -80°C.
Sample viral inactivation was performed by treatment with 1% Triton X-100 (Thermo Fisher Scientific,
#28314) and 0.3% (w/w) tri-(*n*-butyl) phosphate (TNBP) at room temperature for 2 hours.

### 120 Synthesis of the SARS-CoV-2 receptor binding domain (RBD) and

### 121 spike protein

SARS-CoV-2 spike and RBD were generously provided by the Antibody Engineering Programme, Life
Sciences Institute, NUS as described previously [10].

### 124 Spike and RBD-protein based ELISAs

125 IgA and IgG against SARS-CoV-2 antigens including the whole spike and RBD protein were titrated using quantitative ELISA. 96-well flat-bottom maxi-binding immunoplate (SPL Life Sciences, #32296) 126 were coated with 100 ng of SARS-CoV-2 whole spike protein or 200ng of RBD protein at 4 °C 127 overnight. After three washes in Phosphate Buffer Saline (PBS), 350 µL of blocking buffer [4% skim 128 milk in PBS with 0.05% Tween 20 (PBST)] was added to each well. After incubation for 1.5 hours, the 129 plate was washed three times with PBST. 100 µL of 10-times diluted human milk samples, or 100-times 130 diluted human plasma samples were added to each well for 1-hour incubation. Plate was then washed 131 132 three times with PBST followed by 1-hour incubation in the dark with 100 µL of 5000-times diluted goat anti-human IgG-HRP (Invitrogen, #31413), or 5000-times diluted F(ab')2 anti-human IgA-HRP 133 (Invitrogen, #A24458). Plate was washed three times in PBST and incubated for 3 minutes with 1-Step 134 135 Ultra TMB-ELISA (Thermo Scientific, #34029), 100 µL per well. Reaction was stopped with 100 µL 136 of 1 M  $H_2SO_4$  and optical density at 450nm (OD<sub>450</sub>) was measured using a microplate reader (Tecan Sunrise). OD<sub>450</sub> was calculated by subtracting the background signal from sample binding to the 137 138 blocking buffer. Experiments were performed at least three times.

### 139 **Pseudovirus neutralization test (PVNT)**

The PVNT assay was conducted as described previously [11]. Briefly, the ACE2 stably expressed CHO 140 141 cells were cultured at  $5 \times 10^4$ /mL cells in complete medium for 24 hours. 80-times diluted plasma were incubated with 50,000 lentiviral particles (representative of the SARS-CoV-2 Wuhan-Hu-1 strain) in a 142 total volume of 50 µL at 37 °C for 1 hour. This mixture was added to the CHO-ACE2 monolayer cells 143 and left incubated for 1 hour to allow pseudotyped viral infection. Subsequently, complete medium was 144 added at 150 µL/well for further incubation of 48 hours. After two washes with PBS, 100 µL of ONE-145 gloTM EX luciferase assay reagent (Promega, #E8130) was added to each well and the luminescence 146 values were recorded. The percentage neutralization was calculated as follows: 147

148

 $Neutralization\% = \frac{Readout (unknown) - Readout (infected control)}{Readout (uninfected contorl) - Readout (infected control)} \times 100\%$ 

### 149 Breastmilk/plasma inactivation and peptide based ELISA

Both plasma and BM samples were inactivated with Triton<sup>TM</sup> X-100 (ThermoFisher Scientific, #28314) 150 to a final concentration of 1% for 2 hours at room temperature (RT). A focused epitope screen was 151 performed according to a previously described peptide-based ELISA [12]. S14P5, S20P2, S21P2 and 152 N4P5 are 18-mer peptides derived from SARS-CoV-2 spike protein with immunodominant activities 153 [12,13]. For BM ELISA, Streptavidin coated plates (Life Technologies Pierce, #15126) were coated 154 overnight at 4 degrees with 10 µg/ml peptides diluted in 0.01% polyvinyl alcohol (PVA). Plates were 155 blocked with 0.01% PVA at RT prior to the addition of BM at 1:10 dilution. Goat HRP-conjugated anti-156 157 human IgA (Abcam, #ab97215) diluted at 1: 2,000 in the blocking buffer was used for the detection of peptide specific antibodies. TMB substrate (eBioscience, #00-4201-56) was added to the plate for 158 development and the reaction was quenched with 2M sulfuric acid. Absorbance measurements were 159 read at two wavelengths (450nm and 570nm) using the Infinite M200 plate reader (Tecan, firmware 160 161 V 2.02 11/06). Plates were incubated at RT for one hour on a rotating shaker for all steps unless 162 otherwise stated and washed thrice with 0.1% PBST in between steps.

163 For plasma ELISA, Maxisorp plates (Thermofisher Scientific, #442404) were coated overnight at 4 164 degrees with 1  $\mu$ g/ml of Neutravidin (ThermoFisher Scientific, #31050) diluted in PBS. Plates were 165 blocked with 0.01% PVA followed by the addition of 1:100 inactivated plasma samples. The subsequent 166 steps followed the same sequence as mentioned above.

### 167 Multiplex microbead-based immunoassay

Quantification of cytokine levels in the plasma samples of convalescent and healthy mothers was performed by multiplex microbead-based immunoassays. Plasma samples were treated with 1% Triton<sup>TM</sup> X-100 solvent detergent for virus inactivation [14]. Concentrations of immune mediators were determined using the Luminex<sup>TM</sup> assay (HCYTOMAG-60K-41plex) (Millipore Merck). Plasma from participants (n=7 from each group) and standards were incubated with fluorescent-coded magnetic beads pre-coated with capture antibodies in a 96-well plate. Biotinylated detection antibodies were incubated with the cytokine-bound beads for an hour. Streptavidin-PE was then added for another 30
mins before the acquisition of data using xPONENET<sup>®</sup> 4.0 (Luminex Corporation, USA) software. Data
was analysed using the Bio-Plex Manager<sup>TM</sup>6.1.1. Standard curves were generated with a 5-PL (5parameter logistic) algorithm, reporting values of median fluorescence intensity (MFI) and
concentration data.

Real time reverse transcriptase polymerase chain reaction (RT-PCR) for COVID-19 PCR swabs were
obtained from amniotic fluid, umbilical cord, placental, umbilical cord blood, maternal blood and high
vaginal swabs and breast milk [15,16].

182 The placenta specimen was fixed in formalin overnight before representative sections were obtained 183 from the umbilical cord, placental membranes and placental disc. The tissue was subsequently 184 processed and stained with hematoxylin and eosin for microscopic examination.

### 185 Statistical Analysis

The OD of samples obtained by subtracting the background signals and normalizing the samples against
a negative control to account for interpolate variations. Data analyses were performed using GraphPad
Prism (GraphPad Software, version 7.0.0). Unless otherwise stated, statistical significance is defined as
p-values being less than 0.05.

# 190 **Results**

### 191 Clinical demographics of the GIFT cohort

Eight women with a diagnosis of laboratory confirmed COVID-19 during pregnancy participated in the study (S1 Table). Nine women with no antenatal COVID-19 were recruited as controls. On average, COVID-19 convalescent women were  $30.3 \pm 2.4$  years old. Additional characteristics of the study participants and their infants are presented in Table 1. Of the 8 women, 6 had mild COVID-19, with the most common being dry cough, sore throat and malaise, with one having moderate COVID-19 and the remaining person being asymptomatic. None of them progressed towards hypoxia or exhibited signs of

- 198 lower respiratory tract infection (LRTI) evidenced by chest X-ray abnormalities. Consequently, none
- 199 of the subjects required intensive care unit admission, had oxygen requirements, or were intubated.
- 200 Individual clinical demographics of the convalescent women are listed in S2 Table. Extensive testing
- 201 of placental and umbilical cord samples as well as infant throat swabs all produced negative PCR results
- 202 for COVID-19 (detailed reporting of results in S3 Table).

#### 203 Table 1. Demographic and clinical characteristics of the cohort.

Maternal Characteristics	Cases (n=8)	Controls (n=9)
Age (average; years) (standard	30.3 ± 2.4	32.1 ± 2.5
deviation, SD)		
Race/ethnicity:		
Chinese	1	6
Malay	3	2
Indian	2	1
Caucasian	2	0
BMI (SD)	27 ± 2.2	25.7 ± 1.5
No past medical history	7	8
Other co-morbidities if any		
- Hepatitis C carrier	1	2
- Gestational diabetes mellitus (GDM)	0	1

- Smoking	1	1
- Pre-eclampsia	0	0
Antenatal fetal anomaly scan	No abnormalities detected	No abnormalities detected
Occurrence of mastitis during	0	0
the study period		
Timing of COVID-19		
infection:		
First trimester	2	-
Second trimester	2	-
Third trimester	4	-
Severity		
Symptomatic	6 mild, 1 moderate	-
Asymptomatic	1	-

Infant Characteristics	Cases (n=8)	Controls (n=9)
Female	6	6
Gestational age when born (weeks) (SD)	39 ± 2	39 ± 1
Growth at birth:		
Birth weight (kg) (SD)	$3.517 \pm 0.261$	$3.108 \pm 0.376$

Length (cm) (SD)	$50.5 \pm 1.2$	50.6 ± 1.3
Occipital frontal circumference	$34.5\pm0.7$	$33.3 \pm 0.7$
(cm) (SD)		
Breastfeeding status:		
Exclusive	6	9
Mixed feeding	2	0

#### 205

The eight infants were all born full term with mean gestational age (SD) of  $39 \pm 2$  weeks and had a mean birth weight (SD) of  $3.517 \pm 0.261$  kg. One infant required neonatal intensive care unit stay for 2 days for transient tachypnea of the newborn and was given supplemental oxygen therapy. All infants were breastfed up to 3 months, two of whom were supplemented with formula milk during the same period.

211 It remains controversial whether SARS-CoV-2 can be vertically transmitted and if so, what damage it 212 might cause to the developing child and the maternal-foetal interface i.e., the placenta, especially in 213 continued pregnancy post convalescence from antenatal COVID-19 [17-19]. To address that question, 214 histological examination of placental samples was done to determine if there were notable pathologies 215 or abnormalities. While all 8 samples did not show the presence of SARS-CoV-2, three placentae (CS02, 216 CS03, CS07) showed signs of acute inflammation (Fig 1). Neutrophils were seen in the subchorionic 217 fibrin, indicating subchorionitis. There was no spread of the neutrophils into the chorion or amnion. A 218 mild corresponding foetal inflammatory response was also seen in the umbilical arteries and veins of 219 one of the placentas (CS03). The placenta of CS05 had signs of maternal-foetal malperfusion, and this 220 placenta was also hypoplastic at 389g at 38+0 weeks gestation). However, CS05 had concomitant gestational diabetes mellitus. 221





Fig 1. Neutrophilic infiltration present in the placental of convalescent mothers. Microscopic
analysis shows a neutrophilic infiltrate in the subchorionic region of the placenta of three patients - (A)
patient CS2, H&E x 100, (B) patient CS3, H&E x100, (C) patient CS7, H&E x100. (D) Higher power
view of the inflammatory process (patient CS2, H&E x200).

227

# 228 Convalescent mothers carry SARS-CoV-2 specific antibodies in

### 229 their blood

We first confirmed the presence of IgG antibodies targeting SARS-CoV-2 spike protein (Fig 2A) and spike protein RBD (Fig 2B) in all mothers' plasma 1-month post-partum. Plasma IgA antibodies targeting the same antigens were expressed more variably; they were detected in ~50% of the convalescent mothers (Fig 2C, D).





Fig 2. Spike and RBD-specific IgG and IgA present in maternal plasma of convalescent mothers. Using a protein-based ELISA, maternal plasma from control (CT01- CT10) and convalescent (CS01-CS07) mothers obtained 1-month post-partum were used for the detection of spike (A and C) and RBD (B and D) specific IgG and IgA antibodies. The bar graphs represent the normalized average signals of antibodies binding to the respective proteins. Convalescent mothers (CS samples) are arranged in ascending order according to their time from COVID diagnosis to delivery.

Most convalescent maternal plasma were able to neutralize SARS-CoV-2 pseudoviruses, albeit to 243 varying extents (Fig 3). Interestingly, plasma from one mother - CS04 - showed no detectable 244 pseudovirus neutralizing ability despite spike- and RBD-specific IgG antibodies being present and 245 comparable to other convalescent mothers. These antibodies are likely to confer some degree of 246 protection against SARS-CoV-2 infections. It is worth noting that neutralization capacity did not 247 248 correlate with the length of time between disease resolution and point of sampling. In other words, the 249 women who were infected at an earlier stage of pregnancy did not necessarily produce lower titers as 250 one would expect due to antibody decay and contraction of the humoral response.



251

Fig 3. Neutralization of SARS-CoV-2 pseudovirus using maternal plasma. Plasma from control (n=10) and convalescent mothers (n=7). Bar graphs represent the average percentage neutralization. Convalescent mothers (CS samples) are arranged in ascending order according to their time from COVID diagnosis to delivery.

256

257 Four immunodominant epitopes S14P5, S20P2, S21P2 and N4P5 were previously identified to be associated with disease severity in adults (age  $41 \pm 13$ , years  $\pm$  standard deviation) [12]. Importantly, 258 259 antibodies against S14P5 and S21P2 epitopes were able to neutralize SARS-CoV-2-infection 260 [12,13,20]. Hence, we evaluated the presence of antibodies against the four immunodominant epitopes in our cohort. A significant increase in the levels of IgG against S21P2 (Mann Whitney, two tailed, 261 p=0.0205) was observed in the plasma of convalescent mothers compared to controls (S1 Fig C). No 262 significant difference in the levels of IgG against the other three immunodominant epitopes in the 263 264 plasma of convalescent mothers compared to controls was found (S1 Fig A, B, and D). The IgA levels against the four immunodominant epitopes in convalescent mothers were mostly below the limit of 265 detection. Hence differences in IgA levels in the plasma between both groups cannot be accurately 266 267 determined (S2 Fig).

### 268 SARS-CoV-2 specific antibodies transferred in-utero to the child

### 269 wanes over 6 months

270	An important component of passive immunity is the suite of antibodies transferred across the placenta
271	from mother to child. As shown in Fig 4A and B, compared to the mothers, SARS-CoV-2 specific IgG
272	antibodies were detected in the infants' sera at comparable or higher levels at birth, showing passive
273	immunity to be successfully transferred via the placenta. We observed a steady decrease in plasma IgG
274	levels in infants from birth to 6 months of age, where the signal approached the lower detection limit.
275	The transplacental transfer ratios for spike- and RBD-specific IgG antibodies ranged from 0.73 to 1.4
276	6 (Fig 4C and D), in alignment with previous COVID-19 studies and other types of pathogens [21-23].



Fig 4. Spike and RBD-specific IgG are passively transferred from convalescent mothers to infants.
(A) Spike and (B) RBD-specific IgG from maternal plasma 1 month post-partum and at three time
points from babies' plasma was determined using ELISA. Transfer ratio at the 1 month timepoint of
(C) spike and (D) RBD-specific IgG from mother to infant was calculated by taking the averaged IgG

signal of baby's over the mother's IgG. Convalescent mothers (CS samples) are arranged in ascendingorder according to their time from COVID diagnosis to delivery.

284

### 285 SARS-CoV-2 specific antibodies are not appreciably secreted into

### 286 convalescent milk

- 287 Apart from transplacental transfer of antibodies, another important mechanism of transmitting passive
- immunity to the child is via BM. Hence, we sought to measure virus-specific antibody titers in milk of
- 289 mothers convalescent from antenatal COVID-19. Generally, minimal SARS-CoV-2 spike- and RBD-
- 290 specific IgG and IgA antibodies were present in milk at 0-3 months postpartum (Fig 5). The same was
- 291 observed for the epitope-specific antibodies (S3 Fig).



#### 292

293 Fig 5. Spike and RBD-specific IgA present in maternal breast milk of convalescent mothers. Using 294 a protein-based ELISA, maternal breast milk from control (CT01- CT10) and convalescent (CS01-295 CS08) mothers obtained at two time points 0-1months and 2-3months post-partum were used for the 296 detection of spike and RBD-specific IgG and IgA antibodies. Breast milk was screened for (A) spike-297 specific IgG, (B) RBD-specific IgG, (C) spike-specific IgA, and (D) RBD-specific IgA. The bar graphs 298 represent the normalized average signals of antibodies binding to the respective proteins. Convalescent mothers (CS samples) are arranged in ascending order according to their time from COVID diagnosis 299 300 to delivery.

We noted a singular case, CS04, who produced S21P2-specific IgA responses in plasma and milk that were significantly higher than others, with no decrease observed up to 3 months postpartum (S2 Fig C, S3 Fig C). Notably, CS04 suffers from chronic high-viral load hepatitis C virus (HCV) infection, where

305 the virus is of genotype GT3a. CS04 did not have unusually high serum IgA (Fig 2C and D). Hence, we asked the question whether HCV genotype GT3a encodes S21P2-like antigens that could induce 306 cross-reactive antibody production. Initial Protein BLAST revealed no significant overlap between 307 S21P2 and HCV proteins, including those encoded by GT3a (S1 Appendix). We then compared CS04 308 309 against CT10, a control mother who was COVID-19-negative but was HCV genotype GT3a-positive 310 with comparable viral loads. Unlike CS04, CT10 did not have any pre-existing antibodies against S21P2 311 (S2 Fig C, S3 Fig C). This suggests that the high titers of S21P2-specific IgA in CS04 were not due to 312 cross-reactive IgA-mediated immunity against HCV. It might be that carriage of HCV results in a 313 stronger mucosa-directed anti-viral response marked by higher titers of anti-S21P2 IgA. Nonetheless, 314 we acknowledge the key limitation of small sample size, given the rarity of co-infections by SARS-315 CoV-2 and HCV in pregnant women; larger studies will be required to clarify interactions or lack 316 thereof between the two viruses.

### 317 Persistence of pro-inflammatory cytokines in convalescent mothers

318 To gain insight on long-term perturbations in the maternal immune system post-COVID 19, we 319 quantified levels of cytokines with a 41-plex microbead-based immunoassay. Using plasma samples of 320 six control and seven convalescent mothers at 1-month post-partum, we could detect 33 out of 41 321 cytokines (Fig 6). As far as the assayed cytokines were concerned, both healthy and convalescent 322 mothers had largely similar signatures. Most of the signals for the detected cytokines were not 323 distributed normally, likely due to the fact that they clustered near the lower limit of detection. Notwithstanding, five cytokines, namely interleukin-17RA (IL-17RA), eotaxin, interferon-gamma 324 produced protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1) and macrophage 325 inflammatory protein-1 $\beta$  (MIP-1 $\beta$ ) exhibited Gaussian distributions and were likely more robust 326 327 biomarkers. Hence, we focused on these cytokines for further analysis. In order to detect cytokines with increased expression in convalescent mothers, we utilized a statistical threshold of p<0.1 due to small 328 329 sample size and low power in this study. We found that pro-inflammatory cytokines IL-17RA (p=0.02) and MCP-1 (p=0.0766) were elevated in convalescent mothers than healthy controls, suggestive of a 330 prolonged inflammatory state long after COVID resolution (Fig 6B and C). 331



332

Fig 6. Cytokine profile differences in healthy and convalescent mothers' plasma. Using 1-month
post-partum plasma (n=6 for controls and n=7 for cases), cytokines were evaluated using the 41-plex
Luminex<sup>TM</sup> assay. (A) A representation of all cytokines that were detected, (B) IL-17RA levels and (C)
MCP-1. Convalescent mothers are represented in red while healthy controls are represented in black.
Bar graphs represent the average log(concentration) from the samples from the respective groups in A
while the measured concentrations were used for B and C.

339

# 340 SARS-CoV-2 specific antibody titers in convalescent milk are

- **boosted with a single dose of Pfizer/BioNTech's BNT162b2**
- 342 **mRNA vaccine**





Fig 7. Increased secretion and production of spike-specific IgA and IgG antibodies postvaccination in convalescent mothers. Breast milk from three nursing convalescent mothers were collected at 4 time points, prior to vaccination (0), 3 days post-vaccination, 7 days post-vaccination,

and 30 days post-vaccination for a (A and C) spike and (B and D) RBD protein-based IgA and IgG
ELISA assay. The x-axis refers to the number of days post-vaccination.

358

# 359 **Discussion**

In this study, we show that women who had acquired COVID-19 during pregnancy have high levels of circulating virus-specific IgG in their blood relative to control mothers. Furthermore, spike- and RBD-specific IgG levels in maternal circulation were maintained at relatively high levels regardless of gestation when SARS-CoV-2 infection was acquired in pregnancy; virus-specific IgG could be detected in infants at birth when mothers had acquired antenatal COVID-19 as early as 15 weeks. However, circulating spike- and RBD-specific IgG levels in infants born to convalescent COVID-19

mothers declined to negligible levels by three months of life. These findings are all consistent with the

known patterns of acute gestational infections and passive immunity.

While virus-specific IgG was robustly expressed in convalescent plasma, virus-specific IgA levels in the blood were far more variable. IgA is a marker of acute infection and wanes just as IgG expression starts to pick up during disease resolution [24,25]. Hence, the expectation is that the shorter the interval between virus clearance and the point of sampling, the higher the IgA titers measured at the time of sample collection. We did not see such a clear pattern, which may be due to our small sample size and other factors related to host genetics and the environment that may modulate the plasma IgA response.

It is worth noting that, of the placental samples examined, CS02, CS03 and CS07 showed up
abnormal findings indicative of acute inflammation, more than 50 days after their nasopharyngeal
swab tested negative by PCR. These findings are broadly consistent with previous studies
documenting acute inflammatory pathology, maternal vascular malperfusion, fibrinoid changes and
macrophage infiltration [26,27]. Most of the literature on placental pathology in the context of

380 COVID-19 in pregnancy look mainly at acute perinatal infection - trophoblast necrosis and chronic histiocytic intervillositis are common in cases of vertical transmission, whereas materno-foetal 381 malperfusion and villitis are common where there is no vertical transmission. To our knowledge, there 382 are no reports of placental pathology in women convalescent from antenatal COVID-19 at the point of 383 384 delivery. Interestingly, the four convalescent mothers whose placentae showed abnormal 385 characteristics also showed the lowest titers of virus-specific IgA in their blood. Plasma IgA is 386 predominantly monomeric and capable of engaging FcaRI (also known as CD89) on myeloid cells, 387 presumably to trigger the first line of anti-viral defense. One may speculate that placental 388 granulocytes perform a largely sentinel role to prevent compromise of the placental barrier, and in the 389 absence of high amounts of plasma IgA indicative of active infection, they might be continually and 390 preferentially mobilized to the placenta leading to low levels in the circulation [28]. Inefficient transplacental antibody transfer has been previously reported in a small cohort study of 391 392 COVID-19 mothers [22]. However, we did not see this particular effect in our cohort, even in the mothers who acquired COVID-19 in the third trimester and whose placentae exhibited signs of 393 394 inflammation and potential tissue damage. These discrepancies might be due to differences in severity stratification (ratio of asymptomatic: mild: moderate: severe was 6:9:3:4 in Atyeo et al. versus 1:6:1:0 395 396 in our cohort) and symptom onset to delivery (median of 30.5 days in Atyeo et al. versus 98.5 days in 397 our cohort). Also, transplacental transfer occurs most efficiently late into the third trimester, and so 398 infections occurring and resolving earlier in the first and second trimesters are less likely to impact 399 transfer [29].

400 In our study, we noted a significant elevation of IL-17RA and a trend of increased MCP-1 in

401 convalescent mothers relative to controls (Fig 6B and C). IL-17RA is a soluble receptor of IL-17A,

thereby preventing the latter's association with cell surface receptors. IL-17A has been implicated in

403 SARS-CoV-2 pathogenesis with elevated peripheral IL-17 levels and Th17 infiltration in the lungs of

404 COVID patients [30,31]. The persistence of IL-17A together with other inflammatory cytokines such

405 as IL-12p70, stem cell factor, and IL-1 $\beta$  was discovered in patients up to 180 days post-infection [32].

406 In agreement with our findings, COVID-19 patients were found to have increased IL-17RA levels

407 during the acute phase, especially in those with milder symptoms [33]. Hence, enhanced IL-17RA 408 may have a protective role in limiting the downstream effects of IL-17; elevated IL-17RA levels may be a prognostic marker of mild disease in pregnant and lactating women. MCP-1 is the other cytokine 409 that was slightly elevated in convalescent mothers relative to control mothers. It is produced by 410 411 monocytes and macrophages to regulate the migration and infiltration of natural killer cells, monocytes, and T cells [34]. Greater MCP-1 expression characterizes patients with mild COVID-19, 412 413 suggestive of potential roles in mitigating severity [35]. However, we note that the lack of severe 414 cases in our cohort limits us from investigating whether high IL-17RA and MCP-1 levels are true 415 predictors of mild disease. In breast milk, low levels of spike-specific IgG were secreted into 2 out of 8 convalescent women's 416 BM. This is consistent with the existing dogma that IgG is rarely released into milk; the dominant 417

418 isotype is IgA. Even so, virus-specific IgA was only present in a subset of convalescent mothers' milk
419 samples. This is somewhat expected as IgA levels are not maintained throughout infection and have
420 been found to be lowest on the outset in mild cases, where most of the subjects in our cohort fall
421 under [24].

We further delineated the humoral response to linear B cell epitopes that have been previously 422 423 described to be immunodominant. There are certain advantages in investigating these epitopes instead 424 of conformational ones -(1) the system is considerably cheaper to set up for further validation 425 studies, and (2) it is easier to prime cells with peptides which can be synthesized conveniently and do 426 not require complex purification and refolding protocols. We found that most linear epitopes were generally not well-recognized by antibodies present in sera and milk from convalescent mothers. This 427 428 might be due to the fact that long periods of time had passed between COVID-19 recovery and sampling points; the antibody levels waned, similar to that for other infections. One notable exception 429 is S21P2, where epitope-specific IgG was significantly elevated in convalescent plasma compared to 430 controls. In particular, CS04 produced extremely high levels of S21P2-specific IgA in the BM by 431 432 mechanisms unknown to us, although preliminary analysis has excluded HCV antigen cross-reactivity as one possible factor. Nonetheless, much of these signals were non-specific and could also be 433

detected in controls who had non-SARS-CoV-2 coronavirus infection or non-coronavirus antenatalURTI.

Given that convalescent sera do contain high levels of spike- and RBD-specific IgG and yet exhibit 436 low, variable neutralization capacities, we infer that most of the IgG are poorly functional in terms of 437 438 blocking receptor binding, which is consistent with a previous report showing low neutralizing antibody titers in mild cases [36]. The current design of the mRNA vaccines utilizes the 2P mutated 439 440 spike to stabilize its pre-fusion conformation. As these convalescent women had not received the 441 vaccine prior to infection, their immune systems likely encountered virions that had a mix of pre-442 fusion and post-fusion trimers, the latter having evolved to perhaps fulfil immunoevasive functions 443 [37]. The consequence for these individuals is the production of weakly neutralizing antibodies that 444 primarily target the post-fusion conformational epitopes. Had the infected individuals produced 445 strongly neutralizing antibodies, those antibodies would have been predominantly raised against the pre-fusion conformation. Given that a single dose of the Pfizer mRNA vaccine was sufficient to boost 446 virus-specific IgG and IgA responses in mothers who had long convalesced from natural SARS-CoV-447 448 2 infection, we speculate that the booster-elicited antibodies are directed against both the pre- and post-fusion forms; recall responses are activated in cells recognizing the post-fusion spike, and 449 450 primary responses are generated in response to the vaccine-encoded pre-fusion spike. Together, these findings underscore the importance of receiving the vaccine even after recovery from natural 451 infection. Additionally, given the lack of safety and efficacy data in administering vaccines to infants, 452 breastfeeding after vaccination could be a viable alternative to conferring some form of mucosal 453 immunity to the vulnerable children, after the loss of transplacentally transferred antibodies at 3 454 months of age. 455

456 A key limitation of our study is the cohort size. Most of our samples were collected early on in the 457 pandemic before Singapore introduced a slew of effective public health measures to stymie the spread 458 of the virus, including travel restrictions, social distancing, and a lockdown. Due to this unique 459 situation, relatively few people were infected in the first wave from April to August 2020. Limited

- 460 community transmission between August 2020 and August 2021 prevented further subject recruitment461 and sample collection.
- 462 In the context of the present situation, we note two caveats, namely the current dominance of Delta
- 463 and Omicron over early pandemic variants and the high rate of vaccine uptake by the resident
- 464 population (~92% as of 31<sup>st</sup> March 2022). These two factors preclude meaningful head-to-head
- 465 comparisons of more recent studies against our cohort in the GIFT study where immunologically
- 466 naïve individuals were infected with variants possessing lower immunoevasive abilities.
- 467 Notwithstanding these differences, our studies provide insights into the pathogenesis of COVID-19 in
- the under-studied demographics of pregnant and lactating women as well as infants born to them.

# **469 Author contributions**

- 470 Y.G. Formal analysis, Investigation, Methodology, Validation, Writing Original draft preparation,
- 471 Writing review & editing. J.M.L. Conceptualization, Formal analysis, Funding acquisition,
- 472 Investigation, Project administration, Resources, Validation, Writing Original draft preparation,
- 473 Writing review & editing. J.S.Y.T. Formal analysis, Investigation, Methodology, Visualization,
- 474 Writing Original draft preparation, Writing review & editing. M.S.F.N Formal analysis,
- 475 Investigation, Validation, Writing Original draft preparation, Writing review & editing. L.F.P.N –
- 476 Methodology, Writing review & editing. B.N. Investigation, Methodology, Validation, Writing -
- 477 review & editing. R.G. Investigation, Writing review & editing. P.A.M Resources, Supervision,
- 478 Writing review & editing. Z.A. Resources, Supervision, Writing review & editing. L.Y.L. –
- 479 Funding acquisition, Supervision, Writing review & editing. D.W.Q.L Formal Analysis,
- 480 Investigation, Methodology, Validation, Supervision, Writing review & editing. L.P.C.S –
- 481 Supervision, Writing review & editing. Y.Z. Formal analysis, Investigation, Methodology, Project
- 482 administration, Supervision, Validation, Writing Original draft preparation, Writing review &
- 483 editing. L.W.W. Formal analysis, Investigation, Methodology, Project administration, Supervision,
- 484 Validation, Writing Original draft preparation, Writing review & editing.
- 485 All authors declare that they have no conflicts of interest.

# 486 Acknowledgements

- 487 This work was funded by National University Hospital of Singapore (NUHS) seed grants awarded to
- 488 J.M.L. and L.Y.L. L.W.W. is a recipient of the Singapore National Medical Research Council Open
- 489 Fund Young Investigator Grant (NMRC OF-YIRG; Grant number MOH-000545-00) and an award
- 490 from the A\*STAR Biomedical Research Council (BMRC) Central Research Fund for Use-Inspired
- 491 Basic Research (CRF-UIBR).
- 492 We thank Antibody Engineering Programme, Life Sciences Institute, NUS for providing the purified
- 493 spike protein and RBD. We thank Associate professor Tan Yee Joo from Department of Microbiology

- and Immunology, Yong Loo Lin School of Medicine, NUS for the ACE2 stably expressing CHO cells
- and plasmid encoding SARS-CoV-2 S protein for the pseudotyped lentiviral production. We thank the
- 496 participating mothers and children for their kind donation of samples.

# 498 **References**

499	1.	Eastin C	, Eastin T	. Epidemio	logical char	acteristics of	of 2143	pediatric	patients	with 2019
-----	----	----------	------------	------------	--------------	----------------	---------	-----------	----------	-----------

500 coronavirus disease in China: Dong Y, Mo X, Hu Y, et al. Pediatrics. 2020; doi: 10.1542/peds.2020-

- 501 0702. J Emerg Med. 2020;58(4):712-3.
- 502 2. Kyle MH, Glassman ME, Khan A, Fernández CR, Hanft E, Emeruwa UN, et al. A review of
- newborn outcomes during the COVID-19 pandemic. Semin Perinatol. 2020;44(7):151286-.
- 504 3. Cacho NT, Lawrence RM. Innate Immunity and Breast Milk. Frontiers in Immunology.
  505 2017;8(584).
- 506 4. Demers-Mathieu V, Underwood MA, Beverly RL, Nielsen SD, Dallas DC. Comparison of

 507
 Human Milk Immunoglobulin Survival during Gastric Digestion between Preterm and Term Infants.

508 Nutrients. 2018;10(5):631.

509 5. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Dynamics and

- significance of the antibody response to SARS-CoV-2 infection. medRxiv : the preprint server forhealth sciences. 2020.
- 512 6. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2

513 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases : an official publication

- of the Infectious Diseases Society of America. 2020;71(16):2027-34.
- 515 7. Dong Y, Chi X, Hai H, Sun L, Zhang M, Xie WF, et al. Antibodies in the breast milk of a
- 516 maternal woman with COVID-19. Emerging microbes & infections. 2020;9(1):1467-9.

517 8. Fox A, Marino J, Amanat F, Krammer F, Hahn-Holbrook J, Zolla-Pazner S, et al. Robust and

518 Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk. iScience.

**519** 2020;23(11):101735-.

- 520 9. Gao X, Wang S, Zeng W, Chen S, Wu J, Lin X, et al. Clinical and immunologic features
- among COVID-19-affected mother-infant pairs: antibodies to SARS-CoV-2 detected in breast milk.
- 522 New microbes and new infections. 2020;37:100752.

- 523 10. Raghuvamsi PV, Tulsian NK, Samsudin F, Qian X, Purushotorman K, Yue G, et al. SARS-
- 524 CoV-2 S protein: ACE2 interaction reveals novel allosteric targets. eLife. 2021;10.
- 525 11. Kongsuphol P, Jia H, Cheng HL, Gu Y, Shunmuganathan BDO, Chen MW, et al. A rapid
- 526 simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies. Communications
- 527 Medicine. 2021;1(1):46.
- 528 12. Amrun SN, Lee CY, Lee B, Fong SW, Young BE, Chee RS, et al. Linear B-cell epitopes in
- 529 the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity.
- 530 EBioMedicine. 2020;58:102911.
- 13. Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY-P, Chee RS-L, et al. Two linear epitopes
- 532 on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nature
- 533 Communications. 2020;11(1):2806.
- 534 14. Chan YH, Young BE, Fong SW, Ding Y, Goh YS, Chee RS, et al. Differential Cytokine
- 535
   Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. Front Immunol.
- **536** 2021;12:680188.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
  with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- 539 16. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia
- associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a
  family cluster. Lancet. 2020;395(10223):514-523.
- 542 17. Fan C, Guo Y, Qu P, Wang S, Wang M, Yuan J, et al. No obviously adverse pregnancy
- 543 complications and outcomes of the recovered pregnant women from COVID-19. Reproductive
- 544 toxicology (Elmsford, NY). 2021;100:163-6.
- 545 18. Sharps MC, Hayes DJL, Lee S, Zou Z, Brady CA, Almoghrabi Y, et al. A structured review
- of placental morphology and histopathological lesions associated with SARS-CoV-2 infection.
- 547 Placenta. 2020;101:13-29.

548	19.	Di Girolamo R	, Khalil A	Alameddine S.	D'Angelo E.	Galliani C.	, Matarrelli B.	, et al
								,

- 549 Placental histopathology after SARS-CoV-2 infection in pregnancy: a systematic review and meta-
- analysis. American journal of obstetrics & gynecology MFM. 2021;3(6):100468.
- 551 20. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of
- 552 COVID-19 patients reveals cross-reactivity and correlates of severity. Science (New York, NY).

553 2020;370(6520).

- 554 21. Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al.
- 555 Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer
- 556 Ratios. JAMA Pediatrics. 2021;175(6):594-600.
- 557 22. Atyeo C, Pullen KM, Bordt EA, Fischinger S, Burke J, Michell A, et al. Compromised
- 558 SARS-CoV-2-specific placental antibody transfer. Cell. 2021;184(3):628-42.e10.
- 559 23. Fu C, Lu L, Wu H, Shaman J, Cao Y, Fang F, et al. Placental antibody transfer efficiency and
- 560 maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-
- 1 antibodies. Scientific Reports. 2016;6(1):38874.
- 562 24. Zervou FN, Louie P, Stachel A, Zacharioudakis IM, Ortiz-Mendez Y, Thomas K, et al.
- 563 SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
- 564 Journal of medical virology. 2021;93(9):5409-15.
- 565 25. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in
- 566 COVID-19. Cellular & Molecular Immunology. 2020;17(7):773-5.
- 567 26. Schwartz DA, Morotti D. Placental Pathology of COVID-19 with and without Fetal and
- 568 Neonatal Infection: Trophoblast Necrosis and Chronic Histiocytic Intervillositis as Risk Factors for
- 569 Transplacental Transmission of SARS-CoV-2. Viruses. 2020;12(11):1308.
- 570 27. Menter T, Mertz KD, Jiang S, Chen H, Monod C, Tzankov A, et al. Placental Pathology
- 571 Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion.
- 572 Pathobiology. 2021;88(1):69-77.

573	28.	Facchetti F, Bugatti M, Drera E, Tripodo C, Sartori E, Cancila V, et al. SARS-CoV2 vertical
574	transmi	ssion with adverse effects on the newborn revealed through integrated immunohistochemical,
575	electron	n microscopy and molecular analyses of Placenta. EBioMedicine. 2020;59:102951.
576	29.	Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental
577	transfei	in healthy and pathological pregnancies. Clinical & developmental immunology.
578	2012;20	012:985646.
579	30.	Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19
580	associa	ted with acute respiratory distress syndrome. The Lancet Respiratory medicine. 2020;8(4):420-
581	2.	
582	31.	Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol.
583	2020;20	0(6):345-6.
584	32.	Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. Persistent Symptoms
585	and As	sociation With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019
586	Patients	s. Open forum infectious diseases. 2021;8(6):ofab156.
587	33.	Cacciapuoti S, De Rosa A, Gelzo M, Megna M, Raia M, Pinchera B, et al. Immunocytometric
588	analysis	s of COVID patients: A contribution to personalized therapy? Life Sci. 2020;261:118355
589	34.	Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-
590	1): an c	verview. Journal of interferon & cytokine research : the official journal of the International
591	Society	for Interferon and Cytokine Research. 2009;29(6):313-26.
592	35.	Xi X, Guo Y, Zhu M, Wei Y, Li G, Du B, et al. Higher expression of monocyte chemotactic
593	protein	1 in mild COVID-19 patients might be correlated with inhibition of Type I IFN signaling.
594	Virolog	y Journal. 2021;18(1):12.
595	36.	Chen X, Pan Z, Yue S, Yu F, Zhang J, Yang Y, et al. Disease severity dictates SARS-CoV-2-
596	specific	e neutralizing antibody responses in COVID-19. Signal Transduction and Targeted Therapy.
597	2020;5	(1):180.
598	37.	Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM, Jr., et al. Distinct conformational
599	states o	f SARS-CoV-2 spike protein. Science (New York, NY). 2020;369(6511):1586-92.